Vous êtes ici

Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc. logo
Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Diversified Industries
Symbole: 
MYCO
Indice CSE: 
Devise: 

Mydecine Innovations Group Inc. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.

Vous êtes ici

Mydecine Innovations Group Inc. (MYCO)

SEDAR Information

Information d'entreprise

Addresse
1890 – 1075 West Georgia Street
Vancouver, BC V6E 3C9
Canada
Téléphone
604-687-2038
Courriel
hello@mydecineinc.com
URL
http://www.mydecineinc.com
Date d’inscription à la cote
Vendredi, octobre 6, 2023
Agent de transfert
Endeavor Trust Corporation
Vérificateur
HDCPA Professional Corporation

Capitalisation

Capitalisation: 
61755385
Réservé à l'émission: 
22583791

Company Officers

David Joshua Bartch, President and Chief Executive Officer
John Ross, Chief Financial Officer and Corporate Secretary
Damon Michaels , Chief Operations Officer
Robert Roscow, Chief Science Officer
Rakesh Jetly, Chief Medical Officer
Jim Gunning, Chief Marketing Officer

Bulletins